These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32941520)

  • 1. Standardized metrics can reveal region-specific opportunities in community engagement to aid recruitment in HIV prevention trials.
    Broder GB; Lucas JP; Davis J; Wallace SE; Luthuli N; Baepanye K; White RR; Bolton M; Blanchette C; Andrasik MP
    PLoS One; 2020; 15(9):e0239276. PubMed ID: 32941520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collateral benefits: how the practical application of Good Participatory Practice can strengthen HIV research in sub-Saharan Africa.
    Baron D; Essien T; Pato S; Magongo M; Mbandazayo N; Scorgie F; Rees H; Delany-Moretlwe S
    J Int AIDS Soc; 2018 Oct; 21 Suppl 7(Suppl Suppl 7):e25175. PubMed ID: 30334610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.
    Hanass-Hancock J; Carpenter B; Reddy T; Nzuza A; Gaffoor Z; Goga A; Andrasik M
    Trials; 2021 Dec; 22(1):897. PubMed ID: 34895272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study.
    Newman PA; Rubincam C; Slack C; Essack Z; Chakrapani V; Chuang DM; Tepjan S; Shunmugam M; Roungprakhon S; Logie C; Koen J; Lindegger G
    PLoS One; 2015; 10(8):e0135937. PubMed ID: 26295159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative study of stakeholder and researcher perspectives of community engagement practices for HIV vaccine clinical trials in South Africa.
    Dietrich JJ; Munoz J; Tshabalala G; Makhale LM; Hornschuh S; Rentas F; Mulaudzi M; Laher F; Andrasik MP
    J Community Psychol; 2023 Apr; 51(3):998-1015. PubMed ID: 36342974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadening community engagement in clinical research: Designing and assessing a pilot crowdsourcing project to obtain community feedback on an HIV clinical trial.
    Day S; Mathews A; Blumberg M; Vu T; Rennie S; Tucker JD
    Clin Trials; 2020 Jun; 17(3):306-313. PubMed ID: 32009466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
    Corey L; Gilbert PB; Juraska M; Montefiori DC; Morris L; Karuna ST; Edupuganti S; Mgodi NM; deCamp AC; Rudnicki E; Huang Y; Gonzales P; Cabello R; Orrell C; Lama JR; Laher F; Lazarus EM; Sanchez J; Frank I; Hinojosa J; Sobieszczyk ME; Marshall KE; Mukwekwerere PG; Makhema J; Baden LR; Mullins JI; Williamson C; Hural J; McElrath MJ; Bentley C; Takuva S; Gomez Lorenzo MM; Burns DN; Espy N; Randhawa AK; Kochar N; Piwowar-Manning E; Donnell DJ; Sista N; Andrew P; Kublin JG; Gray G; Ledgerwood JE; Mascola JR; Cohen MS;
    N Engl J Med; 2021 Mar; 384(11):1003-1014. PubMed ID: 33730454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing community stakeholder engagement in biomedical HIV prevention trials: principles, practices and evidence.
    Newman PA; Rubincam C
    Expert Rev Vaccines; 2014 Dec; 13(12):1553-62. PubMed ID: 25174764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for stakeholder engagement and COVID-19 related clinical trials' conduct in sub-Saharan Africa.
    Folayan MO; Brown B; Haire B; Babalola CP; Ndembi N
    Dev World Bioeth; 2021 Mar; 21(1):44-50. PubMed ID: 32798320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The trouble with difference: Challenging and reproducing inequality in a biomedical HIV research community engagement process.
    de Wet A; Swartz L; Kagee A; Lesch A; Kafaar Z; Hassan NR; Robbertze D; Newman PA
    Glob Public Health; 2020 Jan; 15(1):22-30. PubMed ID: 31274374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration.
    Duda SN; Farr AM; Lindegren ML; Blevins M; Wester CW; Wools-Kaloustian K; Ekouevi DK; Egger M; Hemingway-Foday J; Cooper DA; Moore RD; McGowan CC; Nash D;
    J Int AIDS Soc; 2014; 17(1):19045. PubMed ID: 25516092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Why Don't You Go Into Suburbs? Why Are You Targeting Us?": Trust and Mistrust in HIV Vaccine Trials in South Africa.
    Thabethe S; Slack C; Lindegger G; Wilkinson A; Wassenaar D; Kerr P; Bekker LG; Mngadi K; Newman PA
    J Empir Res Hum Res Ethics; 2018 Dec; 13(5):525-536. PubMed ID: 30417754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stakeholder engagement to inform HIV clinical trials: a systematic review of the evidence.
    Day S; Blumberg M; Vu T; Zhao Y; Rennie S; Tucker JD
    J Int AIDS Soc; 2018 Oct; 21 Suppl 7(Suppl Suppl 7):e25174. PubMed ID: 30334358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building Partnerships and Stakeholder Relationships for HIV Prevention: Longitudinal Cohort Study Focuses on Community Engagement.
    DeShields RD; Lucas JP; Turner M; Amola K; Hunter V; Lykes S; Rompalo AM; Vermund SH; Fischer S; Haley DF
    Prog Community Health Partnersh; 2020; 14(1):29-42. PubMed ID: 32280121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global Health Diplomacy, Monitoring & Evaluation, and the Importance of Quality Assurance & Control: Findings from NIMH Project Accept (HPTN 043): A Phase III Randomized Controlled Trial of Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand.
    Kevany S; Khumalo-Sakutukwa G; Singh B; Chingono A; Morin S;
    PLoS One; 2016; 11(2):e0149335. PubMed ID: 26901519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
    Edupuganti S; Mgodi N; Karuna ST; Andrew P; Rudnicki E; Kochar N; deCamp A; De La Grecca R; Anderson M; Karg C; Tindale I; Greene E; Broder GB; Lucas J; Hural J; Gallardo-Cartagena JA; Gonzales P; Frank I; Sobieszczyk M; Gomez Lorenzo MM; Burns D; Anderson PL; Miner MD; Ledgerwood J; Mascola JR; Gilbert PB; Cohen MS; Corey L;
    J Acquir Immune Defic Syndr; 2021 May; 87(1):671-679. PubMed ID: 33587505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'It looks like you just want them when things get rough': civil society perspectives on negative trial results and stakeholder engagement in HIV prevention trials.
    Koen J; Essack Z; Slack C; Lindegger G; Newman PA
    Dev World Bioeth; 2013 Dec; 13(3):138-48. PubMed ID: 22998395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community engagement and investment in biomedical HIV prevention research for youth: rationale, challenges, and approaches.
    Ellen JM; Wallace M; Sawe FK; Fisher K
    J Acquir Immune Defic Syndr; 2010 Jul; 54 Suppl 1():S7-11. PubMed ID: 20571425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing a Memory Clinic Model to Facilitate Recruitment into Early Phase Clinical Trials for Mild Cognitive Impairment and Alzheimer's Disease.
    Park L; Kouhanim C; Lee S; Mendoza Z; Patrick K; Gertsik L; Aguilar C; Gullaba D; Semenova S; Jhee S
    J Prev Alzheimers Dis; 2019; 6(2):135-138. PubMed ID: 30756120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention.
    Valente PK; Wu Y; Cohen YZ; Caskey M; Meyers K
    Clin Trials; 2021 Feb; 18(1):17-27. PubMed ID: 32838558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.